Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on November 7, 2023. The filing serves to announce the release of earnings results for the third quarter ended September 30, 2023. The full earnings press release is attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the attached press release (Exhibit 99.1) for detailed financial data. The report highlights the use of non-GAAP financial measures to evaluate ongoing operating trends, excluding items such as impairment charges, amortization, restructuring, and acquisition-related costs.
Material Changes and Adjustments
The filing details the specific adjustments made to derive non-GAAP measures for the current and prior periods:
- Three Months Ended Sept 30, 2023: Adjustments include amortization of acquired intangibles, restructuring charges, unusual litigation, acquisition/integration charges, and foreign currency translation.
- Three Months Ended Oct 1, 2022: Adjustments include the above items plus gains/losses on investment securities and loss on early debt extinguishment.
- Nine Months Ended Sept 30, 2023: Adjustments include milestone payments received related to royalty rights and gains/losses on divestitures.
- Nine Months Ended Oct 1, 2022: Adjustments include impairment charges and loss on early debt extinguishment.
Guidance, Outlook, and Risks
Management utilizes these non-GAAP measures for planning, forecasting, and determining compensation. The filing emphasizes that these measures allow for better comparison with peer businesses by removing the impact of foreign exchange, acquisitions, and divestitures. No specific forward-looking guidance or new risk factors are detailed in this specific 8-K text; investors are directed to the attached press release for management commentary and outlook.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the magnitude of excluded items like amortization and restructuring.
- Assess the impact of foreign currency translation on reported sales growth versus constant currency growth.
- Confirm the status of unusual litigation and restructuring charges mentioned in the adjustments.